30 closest matches · ranked by relevance
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Chronic Thromboembolic Pulmonary Hypertension
Primary: Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) at Rest. — 73.0; 87.2 percent of baseline PVR — p=0.0410
Chronic Thromboembolic Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 72 Participants
Pulmonary Hypertension
Primary: Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance — 8.4; 18.2; 17.7; 20.2 walk distance change from baseline (m)
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Pulmonary Hypertension
Primary: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16 — 38.9; -5.5 Meters — p=<0.0001
Pulmonary Embolism · Pulmonary Thromboembolism
Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Primary: Change in 6-minute Walk Test Distance After 24 Weeks — 45.43; 3.83 m — p=0.002
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Pulmonary Hypertension · Interstitial Lung Disease · Combined Pulmonary Fibrosis and Emphysema
Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 — -9.0; 6.0 meters — p=0.0043
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Valvular Heart Disease
Primary: Rate of Participants With MACCE Events — 3 Participants
Pulmonary Embolism
Primary: Primary Safety Endpoint (Composite): Incidence of Adjudicated Serious Adverse Events (SAE) — 0; 50 Participants
Pulmonary Embolism · Venous Thromboembolism
Primary: Major Adverse Event — 0; 1; 2; 0 participants
Pulmonary Embolism · Acute Pulmonary Embolism · Sub-massive Pulmonary Embolism
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
Pulmonary Hypertension
Primary: Six Minute Walk Distance (6MWD) — 362.5; 362.5; 367.0; 381.0 meters — p=0.072
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
Pulmonary Arterial Hypertension
Primary: Number of Adverse Events — 450; 362; 126; 206 events
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 153; 82; 77; 44 Participants
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale